Unlocking ADC Breakthroughs Through Payload-Linker Chemistry Innovations

Antibody-drug conjugates (ADCs) have emerged as one of the most promising modalities in oncology, and the chemistry behind the payload-linker design plays a pivotal role in efficacy, safety, and manufacturability. In this webinar, Jack Gengcheng Yang, a Senior Director and a seasoned payload-linker expert from WuXi XDC will share how cutting-edge innovations in payload-linker chemistry are driving the next wave of ADC breakthroughs.

The session will explore cleavable and non-cleavable linker technologies, processes for high-quality and cost-effective manufacturing of payload-linkers, new classes of payload-linkers under development, strategies for improving DAR, stability, solubility, and bystander effects with innovative payload-linkers and our proprietary payload linker technologies. Attendees will also learn how WuXi XDC’s one-stop CRDMO platform supports partners from discovery through GMP manufacturing and IND filing. Case studies will highlight how integrated execution accelerates timelines, lowers cost, and de-risks ADC development.